Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia - Nasdaq

Submitted by Anonymous (not verified) on Thu, 07/07/2016 - 05:10

Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomniaNasdaqAmerican Psychiatric Association. DSM-5 Development. Sleep-wake disorders. 2010. Brisbare-Roch C. et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 13(2):150-5; 2007. Citrome L. Suvorexant for insomnia: a ...